OSI 211

Drug Profile

OSI 211

Alternative Names: Liposomal lurtotecan; Lurtotecan liposomal; NX 211; OSI 211L; OSI-211

Latest Information Update: 18 Jun 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator OSI Pharmaceuticals
  • Class Alkaloids; Antineoplastics; Camptothecins
  • Mechanism of Action DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Hodgkin's disease; Ovarian cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 29 Aug 2005 A study has been added to the Cancer therapeutic trials section
  • 05 May 2005 Discontinued - Phase-I for Hodgkin's disease in USA (unspecified route)
  • 05 May 2005 Discontinued - Phase-I for Solid tumours in Canada (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top